Investors ‘beginning to appreciate’ scale of biotech market opportunity
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...
Biotech company Prescient Therapeutics has given investors a glimpse into the progress of it’s next-generation...
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke,...
CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have...
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its...
The US Food and Drug Administration has assigned a fast track designation to a new...
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing...
The terrible news this week that Tmunity Therapeutics, a clinical stage biotherapeutics company, has halted...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.